Table 3.

Number (and rate) of specific harm reduction interventions identified in provincial and territorial policy documents

Case (no. of documents within cases)	Harm reduction (unspecified)	Needle/syringe distribution	Naloxone	Supervised injection or consumption	Low-threshold opioid agonist treatment	Buprenorphine/naloxone (Suboxone)	Drug checking	Safer inhalation kits
British Columbia (10)	208 (20.8)	31 (3.1)	6 (0.6)	22 (2.2)	0 (0.0)	1 (0.1)	0 (0.0)	3 (0.3)
Alberta (4)	78 (19.5)	9 (2.3)	0 (0.0)	2 (0.5)	0 (0.0)	0 (0.0)	0 (0.0)	1 (0.3)
Saskatchewan (3)	253 (84.3)	109 (36.3)	0 (0.0)	38 (12.7)	0 (0.0)	0 (0.0)	0 (0.0)	1 (0.3)
Manitoba (7)	80 (11.4)	13 (1.9)	1 (0.1)	2 (0.3)	0 (0.0)	0 (0.0)	1 (0.1)	2 (0.3)
Ontario (7)	9 (1.3)	1 (0.1)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Quebec (11)	42 (3.8)	11 (1.0)	0 (0.0)	17 (1.5)	5 (0.5)	0 (0.0)	1 (0.1)	0 (0.0)
New Brunswick (1)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Nova Scotia (4)	63 (15.8)	38 (9.5)	2 (0.5)	0 (0.0)	1 (0.3)	27 (6.8)	0 (0.0)	0 (0.0)
Prince Edward Island (1)	6 (6.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Newfoundland and Labrador (2)	5 (2.5)	2 (1.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Yukon (0)	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Northwest Territories (2)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Nunavut (2)	9 (4.5)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Canada (54)	753 (13.9)	214 (4.0)	10 (0.2)	81 (1.5)	6 (0.1)	28 (0.5)	2 (0.04)	7 (0.1)

n/a not applicable